BioCentury | Mar 29, 2012
Distillery Therapeutics

Indication: Neurology

...in mouse models of neurodegenerative disease, stroke and viral encephalitis. Discovery stage CNR2 agonists from Organix Inc....
BioCentury | Nov 3, 2008
Company News

Galenea, Organix Inc., Case Western Reserve University, University of North Carolina, Tufts University School of Medicine deal

...Galenea received exclusive, worldwide rights from Organix and the universities to develop and commercialize preclinical serotonin...
...to develop and commercialize preclinical serotonin (5-HT2C) receptor agonists to treat obesity and related disorders. Organix...
...undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp. , Cambridge, Mass. Organix Inc....
BioCentury | Oct 29, 2008
Company News

Galenea in-licenses 5-HT2C agonists

...Mass.) received exclusive, worldwide rights to develop and commercialize selective serotonin (5-HT2C) receptor agonists from Organix...
...at Chapel Hill. Galenea will develop the preclinical compounds to treat obesity and related disorders. Organix...
Items per page:
1 - 3 of 3
BioCentury | Mar 29, 2012
Distillery Therapeutics

Indication: Neurology

...in mouse models of neurodegenerative disease, stroke and viral encephalitis. Discovery stage CNR2 agonists from Organix Inc....
BioCentury | Nov 3, 2008
Company News

Galenea, Organix Inc., Case Western Reserve University, University of North Carolina, Tufts University School of Medicine deal

...Galenea received exclusive, worldwide rights from Organix and the universities to develop and commercialize preclinical serotonin...
...to develop and commercialize preclinical serotonin (5-HT2C) receptor agonists to treat obesity and related disorders. Organix...
...undisclosed upfront payment and be eligible for milestones and royalties. Galenea Corp. , Cambridge, Mass. Organix Inc....
BioCentury | Oct 29, 2008
Company News

Galenea in-licenses 5-HT2C agonists

...Mass.) received exclusive, worldwide rights to develop and commercialize selective serotonin (5-HT2C) receptor agonists from Organix...
...at Chapel Hill. Galenea will develop the preclinical compounds to treat obesity and related disorders. Organix...
Items per page:
1 - 3 of 3